Decades-Old Heart Therapy Shows Surprising Promise for Alzheimer's Memory Loss

An Unlikely Candidate for Brain Disease

The idea sounds almost too simple: strap inflatable cuffs around a patient's legs, squeeze them in rhythm with their heartbeat, and watch their memory improve. Yet that is precisely what a newly published clinical trial is suggesting. A treatment called External Counterpulsation — or ECP — originally developed to help failing hearts, has now shown striking results in patients with early Alzheimer's disease, offering a rare glimmer of hope in a field that has struggled to produce effective therapies.

The 12-month, multicenter, blinded, randomized, sham-controlled trial enrolled 190 patients with early Alzheimer's disease, including those with mild cognitive impairment due to Alzheimer's and those with mild Alzheimer's per NIA-AA clinical criteria. The results, published in the *American Journal of Alzheimer's Disease & Other Dementias*, were enough to turn heads in the medical community.

How Squeezing Your Legs Could Help Your Brain

ECP is a non-invasive treatment that involves applying three pairs of inflatable cuffs around the lower legs, upper legs, and buttocks, which continuously inflate and deflate in sync with the patient's heartbeat, increasing blood flow back to the heart. In recent years, preliminary evidence has suggested that ECP may have uses beyond the heart — it could also improve blood flow to the brain.

In the trial, participants received either full-pressure ECP at 150–300 mmHg or a sham treatment at just 25 mmHg, with sessions running three to five times weekly for 35 treatments, then tapering to twice-weekly through six months. The sham group gave researchers a meaningful comparison — patients in both groups felt the cuffs, but only one group received therapeutic pressure.

The Numbers Behind the Breakthrough

According to lead author Jack Juni from Renew Research, "78% of patients with mild cognitive impairment or early Alzheimer's improved over their personal baseline after six months of this non-invasive treatment," with participants gaining an average of five points on standard cognitive scales — "an improvement roughly equivalent to regaining one to two years' worth of lost function."

These improvements were measured using tests of memory, attention, language, and reasoning, as well as assessments of everyday abilities like dressing, eating, and household tasks. Perhaps most encouraging, the benefits persisted through 52 weeks despite treatment cessation at six months. In other words, the brain gains didn't evaporate when therapy stopped. No serious device-related adverse events occurred.

Promising, But Not Without Caveats

ECP is currently approved by the FDA for chest pain, acute myocardial infarction, and congestive heart failure, yet it is rarely recommended or used even for those purposes. That relative obscurity makes its potential second life all the more surprising. The trial authors conclude that "the success of this treatment emphasizes the important role of the vascular system in clinical Alzheimer's disease."

The involvement of private industry interests in scientific research is always a reason for skepticism, especially since robust evidence does not yet exist for ECP as a treatment for cerebrovascular diseases. The trial was funded by Renew Research, the company that owns the ECP device used in the study — a conflict of interest that independent researchers will want to scrutinize carefully. Still, there are good reasons to suspect that ECP might work to improve blood flow to the brain, and possibly brain function as a result. The trial's own conclusions state that full-pressure ECP therapy significantly improved cognition and activities of daily living compared to sham treatment, and that ECP represents a novel therapeutic approach warranting further investigation. For the millions of families navigating an Alzheimer's diagnosis with few effective options, that call for further investigation can't come soon enough.